BioPharmSignal logoBioPharmSignal

Biotech News

TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI

TG Therapeutics (TGTX)TG TherapeuticsClinical readout

Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 months Top-line data expected year-end 2026/ first quarter 2027 NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the completion of enrollment in a

Related news

TGTXTG Therapeutics2026-06-03 11:30 EST

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

TGTXTG Therapeutics2026-06-09 11:30 EST

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

View all latest news

TG Therapeutics

B-Cell-Directed Therapies TG Therapeutics develops and commercializes therapies targeting B cells in multiple sclerosis and other autoimmune diseases. Its portfolio combines an approved anti-CD20 antibody with alternative formulations and an allogeneic cell-therapy program. BRIUMVI BRIUMVI, or ublituximab, is a glycoengineered CD20...

Recent company news

TGTXTG Therapeutics2026-08-03 11:00 EST

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

TGTXTG Therapeutics2026-07-29 11:30 EST

TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update

TGTXTG Therapeutics2026-07-06 11:30 EST

TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia

TGTXTG Therapeutics2026-06-09 11:30 EST

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

TGTXTG Therapeutics2026-06-03 11:30 EST

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

Stock data

Close
49.55 USD
Market cap
5.61B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States